Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2001 1
2002 4
2003 8
2004 4
2005 10
2006 19
2007 21
2008 19
2009 35
2010 45
2011 53
2012 60
2013 85
2014 95
2015 86
2016 79
2017 66
2018 73
2019 62
2020 54
Text availability
Article attribute
Article type
Publication date

Search Results

776 results
Results by year
Filters applied: . Clear all
Page 1
Agomelatine for the treatment of generalized anxiety disorder.
Buoli M, Grassi S, Serati M, Altamura AC. Buoli M, et al. Expert Opin Pharmacother. 2017 Sep;18(13):1373-1379. doi: 10.1080/14656566.2017.1359257. Epub 2017 Jul 28. Expert Opin Pharmacother. 2017. PMID: 28730851 Review.
Agomelatine is a melatonergic antidepressant, approved for the treatment of Major Depressive Disorder (MDD) in Europe and Australia, but not in the United States. ...In addition, agomelatine has not been associated with potential risk of abuse as in case of pregabal
Agomelatine is a melatonergic antidepressant, approved for the treatment of Major Depressive Disorder (MDD) in Europe and Australia,
Agomelatine for depression: expanding the horizons?
Norman TR, Olver JS. Norman TR, et al. Expert Opin Pharmacother. 2019 Apr;20(6):647-656. doi: 10.1080/14656566.2019.1574747. Epub 2019 Feb 13. Expert Opin Pharmacother. 2019. PMID: 30759026 Review.
Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagonist. ...Bipolar depression and seasonal affective disorder may also react favourably. Agomelatine may have specific efficacy on sympto
Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagoni
What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
Potměšil P. Potměšil P. Ther Adv Psychopharmacol. 2019 Jul 7;9:2045125319855206. doi: 10.1177/2045125319855206. eCollection 2019. Ther Adv Psychopharmacol. 2019. PMID: 31312426 Free PMC article. Review.
A successful combination of agomelatine was reported after adjunctive use of agomelatine combined with clomipramine, escitalopram, and venlafaxine in patients with major depression or obsessive-compulsive disorder. ...There have also been two published case reports …
A successful combination of agomelatine was reported after adjunctive use of agomelatine combined with clomipramine, escitalop …
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Chenaf C, Chapuy E, Libert F, Marchand F, Courteix C, Bertrand M, Gabriel C, Mocaër E, Eschalier A, Authier N. Chenaf C, et al. Pain. 2017 Jan;158(1):149-160. doi: 10.1097/j.pain.0000000000000738. Pain. 2017. PMID: 27984527
The isobolographic analysis demonstrated that the combination of agomelatine + gabapentin had additive effects. Agomelatine exerts a clear-cut antihypersensitivity effect in 3 different neuropathic pain models. Its effect is mediated by melatonergic and 5-HT2C recep …
The isobolographic analysis demonstrated that the combination of agomelatine + gabapentin had additive effects. Agomelatine ex …
Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Papakostas GI, et al. J Psychiatr Res. 2018 Jun;101:72-79. doi: 10.1016/j.jpsychires.2018.02.017. Epub 2018 Feb 22. J Psychiatr Res. 2018. PMID: 29554497 Free article. Clinical Trial.

In the overall population, vortioxetine (n = 252) was significantly superior to agomelatine (n = 241) by -2.2 MADRS points (p < 0.01) at week 8. 77% (n = 189/vortioxetine, n = 188/agomelatine) were previously treated with an SSRI (citalopram, escitalopram, paroxe

In the overall population, vortioxetine (n = 252) was significantly superior to agomelatine (n = 241) by -2.2 MADRS points (p < 0.

Agomelatine versus other antidepressive agents for major depression.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Guaiana G, et al. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. Cochrane Database Syst Rev. 2013. PMID: 24343836 Review.
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depressive disorder in comparison with other antidepressants, 2) to review the acceptability of agomelatine in comparison with other antid …
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depre …
Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice.
Ozcan M, Canpolat S, Bulmus O, Ulker N, Tektemur A, Tekin S, Ozcan S, Serhatlioglu I, Kacar E, Ayar A, Kelestimur H. Ozcan M, et al. Fundam Clin Pharmacol. 2019 Apr;33(2):170-180. doi: 10.1111/fcp.12413. Epub 2018 Oct 8. Fundam Clin Pharmacol. 2019. PMID: 30216538
TACR1 mRNA levels were lower in raphe nucleus, PAG, and amygdala of agomelatine-treated diabetic mice. The increase in total antioxidant capacity after agomelatine administration may responsible for its beneficial effect in the prevention of diabetes. We showed that …
TACR1 mRNA levels were lower in raphe nucleus, PAG, and amygdala of agomelatine-treated diabetic mice. The increase in total antioxid …
Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus.
Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Lu Y, et al. Life Sci. 2018 Oct 1;210:177-184. doi: 10.1016/j.lfs.2018.09.003. Epub 2018 Sep 4. Life Sci. 2018. PMID: 30193943
Twenty-one day treatment with agomelatine, fluoxetine or vehicle was assessed in 52 Sprague-Dawley rats undergoing CUMS. ...The mean optical density value of BDNF was significantly higher in the CUMS + agomelatine group than the CUMS and CUMS + fluoxetine groups. Th …
Twenty-one day treatment with agomelatine, fluoxetine or vehicle was assessed in 52 Sprague-Dawley rats undergoing CUMS. ...The mean …
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
Taylor D, Sparshatt A, Varma S, Olofinjana O. Taylor D, et al. BMJ. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888. BMJ. 2014. PMID: 24647162 Free PMC article. Review.
DATA SOURCES: Literature search (Pubmed, Embase, Medline), Cochrane Central Register of Controlled Trials, European Medicines Agency (EMA) regulatory file for agomelatine, manufacturers of agomelatine (Servier). ELIGIBILITY CRITERIA: Double blind randomised placebo …
DATA SOURCES: Literature search (Pubmed, Embase, Medline), Cochrane Central Register of Controlled Trials, European Medicines Agency (EMA) r …
The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents.
Fasipe OJ. Fasipe OJ. IBRO Rep. 2019 Jan 9;6:95-110. doi: 10.1016/j.ibror.2019.01.001. eCollection 2019 Jun. IBRO Rep. 2019. PMID: 31211282 Free PMC article. Review.
This study was designed with the rational aim of discussing the emerging antidepressant agents that are likely to bring positive landmark, tremendous improvement and significant impact to the management of patients with depression disorders. It also elaborates on the Agomelati
This study was designed with the rational aim of discussing the emerging antidepressant agents that are likely to bring positive landmark, t …
776 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback